rethinkTHC Search
Menu
Study breakdown

PET Imaging Shows the Brain's Cannabinoid System Changes Early in Alzheimer's, Differently in Males and Females

Animal StudyPreliminary evidence
The takeaway

PET brain imaging in an Alzheimer's mouse model revealed sex- and age-dependent changes in the endocannabinoid system starting from early-stage disease, with females showing earlier cannabinoid receptor changes.

Alzheimer's researchers, neuroscientists studying the endocannabinoid system, proponents of cannabinoid-based dementia treatments

Sex-dependent endocannabinoid changes detected from early-stage Alzheimer's

What the researchers found

PET imaging revealed dynamic changes in cannabinoid receptor 1 (CB1) and MAGL enzyme availability across Alzheimer's disease progression. At 4 months (early-stage), female AD mice had lower CB1 availability while males had increased MAGL. By 12 months (late-stage), CB1 was significantly reduced in AD mice compared to controls. The pattern of changes was consistently sex-dependent throughout disease progression.

Why it matters

The endocannabinoid system is a potential therapeutic target for Alzheimer's, but this study shows its changes are complex, varying by sex, age, and disease stage. This means cannabinoid-based therapies for Alzheimer's may need to be tailored to the patient's sex and disease stage to be effective.

The numbers in context

4 months: females had lower CB1, males had increased MAGL. 8 months: MAGL reduced in AD frontal cortex, males had higher MAGL than females brain-wide. 12 months: significantly lower CB1 in AD vs controls. MAGL PET imaging responsive to JZL184 inhibitor.

How the study worked

PET-CT imaging study using two radioligands ([18F]FMPEP-d2 for CB1 and [18F]MAGL-2102 for MAGL) in a knock-in Alzheimer's mouse model at 3 ages (4, 8, and 12 months). Findings were supplemented with autoradiography, immunofluorescence, and western blots.

What this study cannot tell us

Mouse model of Alzheimer's that may not fully recapitulate human disease. PET radioligand binding reflects availability, not necessarily function. Relatively small group sizes typical of PET imaging studies. Cannot directly translate timing of mouse disease stages to human disease progression.

How to read the evidence

Preliminary evidence from a PET imaging study in an Alzheimer's mouse model, providing mechanistic insights requiring human validation.

When this study was published

2025 preclinical PET imaging study of endocannabinoid system changes in Alzheimer's.

The bigger picture

Interest in cannabinoid-based Alzheimer's treatments has grown, but this study suggests a one-size-fits-all approach may not work. The endocannabinoid system changes differently in males and females with Alzheimer's, and the therapeutic window may be narrow. PET imaging could help monitor these changes and guide treatment timing.

Questions still open

  • Do sex differences in endocannabinoid system changes in AD translate to humans? Could PET imaging of the endocannabinoid system serve as an early diagnostic tool for Alzheimer's? What is the optimal timing for cannabinoid-based interventions in AD?

Common questions

How does Alzheimer's affect the brain's cannabinoid system?
This study found the endocannabinoid system changes early in Alzheimer's disease and continues to evolve. CB1 receptor availability decreased progressively, while the enzyme MAGL showed complex, sex-dependent changes. These shifts could affect how the brain responds to both its own endocannabinoids and external cannabinoids.
Why do sex differences matter?
Female Alzheimer's mice showed earlier CB1 receptor changes than males, while males showed different MAGL enzyme patterns. This suggests that cannabinoid-based Alzheimer's treatments may need to account for patient sex to be most effective.

Read the original research

Sex- and age-specific sensitivities of the endocannabinoid system in Alzheimer's disease revealed by PET imaging with [18F]FMPEP-d 2 and [18F]MAGL-2102.

Theranostics, 15(8), 3368-3385

Citation

Pees, Anna; Morrone, Christopher Daniel; Tong, Junchao; Rong, Jian; Shao, Tuo; Wear, Darcy; Liang, Steven H; Yu, Wai Haung; Vasdev, Neil. (2025). Sex- and age-specific sensitivities of the endocannabinoid system in Alzheimer's disease revealed by PET imaging with [18F]FMPEP-d 2 and [18F]MAGL-2102.. Theranostics, 15(8), 3368-3385. https://doi.org/10.7150/thno.106592

Explore the wider topic